Personalis, Inc. to Present at EACR Liquid Biopsies Virtual Event
18.11.2020 16:00:00 EET | Business Wire | Press release
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for population sequencing and cancer, today announced that the company will participate in the EACR Liquid Biopsies Virtual Event, November 18-19, including a poster presentation and satellite symposia.
The company will showcase both their platforms, ImmunoID NeXT™ and NeXT Liquid Biopsy™.
ImmunoID NeXT is the first platform to enable comprehensive analysis of both a tumor and its immune microenvironment from a single sample, thus maximizing the biological information that can be generated from a precious tumor specimen.
NeXT Liquid Biopsy, a first-of-its-kind, high-performance exome-wide liquid biopsy assay, provides a unique ability to evaluate the cancer ecosystem and advance the development of next-generation therapies. While solid tumor biopsies remain the standard for the interrogation of the cancer genome, the advent of liquid biopsies has demonstrated there can be more to a cancer’s genotypic profile than that found in a single tissue biopsy. Therefore, the combination of NeXT Liquid Biopsy and ImmunoID NeXT delivers the most comprehensive view of a cancer’s mutational landscape by evaluating both the tissue and blood. NeXT Liquid Biopsy enables investigation into key applications such as spatial and temporal heterogeneity of the tumor, clonal evolution and tumor dynamics in response to therapies, and mechanisms of acquired resistance. In this presentation, we’ll highlight data demonstrating the genomic profiling and assay performance enabled by NeXT Liquid Biopsy through the evaluation of reference standards and patient samples.
Following are details for the Personalis presentations.
Scientific Poster Presentation
|
Poster Number |
Title & Presenter |
Dates |
||
|
40
|
Sensitive detection and monitoring of genetic alterations in circulating cfDNA with an enhanced whole-exome approach
|
NOV 18-19 | Online |
Following are details of an industry-sponsored symposium which will be presented at the meeting.
Satellite Symposia
|
Title |
Title & Presenter |
Dates |
||
|
Sponsored Symposia |
NeXT Liquid Biopsy, A High Performance, Exome-Wide Liquid Biopsy Assay to Study Tumor Dynamics
|
NOV 18-19 | On Demand |
About Personalis, Inc.
Personalis, Inc. is a leader in population sequencing and cancer genomics, with a focus on data, scale, efficiency and quality. Personalis operates one of the largest sequencing operations globally and is currently the sole sequencing provider to the U.S. Department of Veterans Affairs Million Veteran Program (VA MVP). In oncology, Personalis is transforming the development of next-generation therapies by providing more comprehensive molecular data about each patient’s cancer and immune response. The Personalis® ImmunoID NeXT Platform ® is designed to adapt to the complex and evolving understanding of cancer, providing its biopharmaceutical customers with information on all of the approximately 20,000 human genes, together with the immune system, from a single tissue sample. The Personalis Clinical Laboratory is GxP-aligned as well as CLIA’88-certified and CAP-accredited. For more information, please visit www.personalis.com and follow Personalis on Twitter (@PersonalisInc).
Forward-Looking Statements
All statements in this press release that are not historical are “forward-looking statements” within the meaning of U.S. securities laws, including statements relating to attributes or advantages of the ImmunoID NeXT Platform, Personalis’ services for the VA MVP, the company’s business opportunities, leadership or growth, or other future events. Such forward-looking statements involve risks and uncertainties, including those related to the COVID-19 pandemic, that could cause actual results to differ materially from any anticipated results or expectations expressed or implied by such statements. Factors that could materially affect actual results can be found in Personalis’ filings with the U.S. Securities and Exchange Commission, including the company’s most recent reports on Forms 8-K, 10-K and 10-Q, and include those listed under the caption “Risk Factors.” Personalis disclaims any obligation to update such forward-looking statements.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201118005479/en/
Contact information
Investor Relations Contact:
Caroline Corner
investors@personalis.com
415-202-5678
Media Contact:
Jennifer Havlek
pr@personalis.com
www.personalis.com
650-752-1300
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Samos Energy Acquisition Corporation Announces Closing of $230 Million Initial Public Offering13.7.2026 22:42:00 EEST | Press release
Samos Energy Acquisition Corporation (the “Company”) announced today the closing of its initial public offering (“IPO”) of 23,000,000 units, including the full exercise by the underwriters of their overallotment option to purchase an additional 3,000,000 units. The offering was priced at $10.00 per unit, resulting in gross proceeds to the Company of $230,000,000. The units began trading on the New York Stock Exchange (the “NYSE”) under the ticker symbol “SAMO.U” on July 10, 2026. Each unit consists of one Class A ordinary share and one-half of one redeemable warrant, with each whole warrant entitling the holder thereof to purchase one of the Company’s Class A ordinary shares at an exercise price of $11.50 per share. Once the securities comprising the units begin separate trading, the Class A ordinary shares and warrants are expected to be listed on the NYSE under the symbols “SAMO” and “SAMO.WS,” respectively. Of the proceeds received from the consummation of the initial public offerin
Kiinalaiset ja EU:n kansalaiset suhtautuvat luottavaisesti Kiinan ja EU:n tulevan yhteistyön näkymiin: GT survey13.7.2026 21:47:00 EEST | Tiedote
Kiinalla ja Euroopan unionilla on ollut viralliset diplomaattisuhteet jo yli puolen vuosisadan ajan. Diplomaattisuhteiden solmimisesta lähtien suhteet ovat kehittyneet kattavaksi strategiseksi kumppanuudeksi, ja Kiinan ja EU:n välisistä suhteista on tullut yksi maailman vaikutusvaltaisimmista kahdenvälisistä suhteista. Kiinan lisäksi Global Times Institute (GTI) toteutti 16.10.–4.11.2025 kyselytutkimuksen 20 EU:n jäsenvaltiossa, kuten Tanskassa, Ruotsissa, Espanjassa, Belgiassa ja Saksassa. Kysely tehtiin 21 kielellä, mukaan lukien espanjaksi, ranskaksi, saksaksi ja kiinaksi. Vastauksia saatiin yli 16 300, ja ne hyväksyttiin tutkimukseen. Kyselyn tulokset osoittavat, että enemmistö sekä Kiinan että EU:n kansalaisista on kiinnostunut toistensa kulttuureista, suhtautuu luottavaisesti Kiinan ja EU:n talous- ja kauppayhteistyön tulevaisuuteen sekä kannattaa Kiinan ja EU:n välisen yhteistyön vahvistamista globaalissa hallinnassa. Korkea tietoisuus ja halukkuus vuorovaikutukseen Tämä kysely
Actus Nutrition Achieves Certified B Corporation ™ Status13.7.2026 18:51:00 EEST | Press release
Actus Nutrition today announced that it has achieved Certified B Corporation™ status, joining a global community of businesses that value social and environmental performance, accountability, and transparency. For more than 80 years, Actus Nutrition has upcycled dairy-based raw materials into high-value nutrition ingredients used by customers around the world. Earning B Corp certification reflects the company’s belief that business success should create value not only for stakeholders, but also for employees, customers, suppliers, communities, and the environment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260713867540/en/ Actus Nutrition achieves Certified B Corporation status. "We've always believed that how a company operates matters just as much as what it produces," said David Lenzmeier, Chief Executive Officer of Actus Nutrition. "Achieving B Corp certification validates the work our teams do every day to operate r
AIT Worldwide Logistics Welcomes Justin Kosslyn as Chief Digital and Technology Officer13.7.2026 18:02:00 EEST | Press release
Supply chain solutions leader AIT Worldwide Logistics has hired Justin Kosslyn, a tenured software development executive, as its chief digital and technology officer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260713269550/en/ Justin Kosslyn will lead an accelerating digital transformation at AIT Worldwide Logistics, unifying a vastly diverse array of shippers and partners across the globe. In the newly created role, Kosslyn will report directly to President and Chief Operating Officer, Keith Tholan, and lead the company’s global technology strategy, continuing to implement AIT’s existing program while accelerating the next generation of integrated digital, data, AI and customer-facing systems across the organization. “With a history of delivering for companies at the center of global technology and innovation, Justin brings the kind of forward-looking perspective we believe can help AIT lead the next evolution of logist
Labaton Keller Sucharow LLP Launches Corporate Accountability & Governance Task Force13.7.2026 17:46:00 EEST | Press release
Labaton Keller Sucharow LLP is pleased to announce the launch of its new Corporate Accountability & Governance Task Force, designed to help institutional investors advance corporate accountability while pursuing meaningful shareholder recoveries. Created in response to the increasing needs of our clients, the Task Force will provide clients with strategic advice on opportunities to drive positive corporate change through securities and shareholder litigation. This initiative reflects the Firm’s longstanding commitment to protecting investor interests while promoting responsible corporate conduct. Labaton partners with institutional investor clients to pursue cases that not only seek financial recovery but also encourage meaningful corporate reforms and reinforce sound governance practices. The Task Force is chaired by Partners Carol C. Villegas and Domenico “Nico” Minerva, who have led some of the Firm's most significant matters involving corporate accountability and governance reform.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom